We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App





Saladax Biomedical Launches Game-Changing Assays at AACC 2018

By LabMedica International staff writers
Posted on 31 Jul 2018
Print article
Image: Saladax Biomedical has launched a new line of tests for psychiatry in Europe (Photo courtesy of Saladax Biomedical).
Image: Saladax Biomedical has launched a new line of tests for psychiatry in Europe (Photo courtesy of Saladax Biomedical).
Saladax Biomedical Inc. (Bethlehem, PA, USA), a diagnostics company providing kits to test drug blood levels for adherence and personalized dose management, announced the launch of its new line of tests for psychiatry in Europe (CE mark) at AACC 2018. Saladax develops novel blood tests that increase the impact of personalized medicine by bringing chemotherapeutic drug monitoring to oncologists and adherence testing to psychiatrists.

Saladax’s MyCare Psychiatry line provides greater clarity on the causes of treatment failure and may help distinguish medication non-response from lack of adherence. The MyCare Psychiatry panel of tests addresses a critical, unmet need for quickly identifying levels of antipsychotic drugs in a patient’s body. A one-hour turnaround time is possible in a STAT mode within a laboratory. Rapid testing has the potential to reduce treatment failures and to positively impact patient management. The MyCare Psychiatry line will launch with tests for clozapine, quetiapine, aripiprazole, risperidone, olanzapine and paliperidone, five of which are currently available for sale in Europe.

“We engineered the MyCare Psychiatry line based on psychiatrists’ needs and extensive research of the market,” said Dr. Salvatore J. Salamone, Founder/CEO. “The result is a game-changer that delivers clinicians access to rapid quantitative blood levels of the psychotherapeutic drugs their patients are on. The MyCare line delivers a fast and accurate result, giving physicians timely information of high medical value, needed to better treat their patients.”

Related Links:
Saladax Biomedical

Gold Supplier
SARS-CoV-2 IGRA
SARS-CoV-2 IGRA
New
Automated Pipetting Solution
PIPETMAX
New
Gold Supplier
SARS-CoV-2 Genome RNA Controls
AMPLIRUN SARS-CoV-2 RNA CONTROL PANEL
New
Silver Supplier
AUTOSAMPLER - CHORUS ACCESSORY
AUTOSAMPLER - CHORUS ACCESSORY

Print article

Channels

Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.